Trial Profile
A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG) Versus Alectinib (ALECENSA) in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Brigatinib (Primary) ; Alectinib
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms ALTA-3
- Sponsors ARIAD Pharmaceuticals; Takeda; Takeda Development Center Americas
- 08 Mar 2024 This trial has been discontinued in Italy according to European Clinical Trials Database record.
- 24 Oct 2023 Results of an exploratory correlative pooled analysis (n=232) of the association of BL ALK fusion status, as detected by ctDNA, with clinical features and outcomes in ALTA-3, presented at the 48th European Society for Medical Oncology Congress.
- 06 Oct 2023 This trial has been discontinued in Spain according to European Clinical Trials Database record.